Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study

Ewa Orlewska; Beata Kos-Kudła; Jerzy Sowiński; Krzysztof Sworczak; Wojciech Zgliczyński; Elżbieta Andrysiak-Mamos; Anna Babińska; Agata Bałdys-Waligórska; Elżbieta Bandurska-Stankiewicz; Krzysztof Błaut; Paweł Bolko; Wanda Foltyn; Danuta Jakubczyk; Aleksandra Jawiarczyk-Przybyłowska; Roman Junik; Olga Juraniec; Ewelina Lewkowicz; Anna Lewczuk; Beata Matyjaszek-Matuszek; Krzysztof Michałek; Sławomir Mucha; Renata Orłowska-Florek; Marta Peszel-Barlik; Sławomir Pynka; Violetta Rosiek; Marek Ruchała; Joanna Rutkowska; Julia Słynko-Krzyzostaniak; Agnieszka Stefańska; Janusz Strzelczyk; Anhelli Syrenicz; Małgorzata Trofimiuk-Müldner; Joanna Waligórska-Stachura; Ryszard Waśko; Przemysław Witek; Danuta Zalewska-Rydzkowska; Piotr Zdunowski; Anna Zemczak

doi:10.5114/wo.2013.38805

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2013
vol. 17

Send email

Copy url:

abstract:

Original paper

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study

Ewa Orlewska

,

Beata Kos-Kudła

,

Jerzy Sowiński

,

Krzysztof Sworczak

,

Wojciech Zgliczyński

,

Elżbieta Andrysiak-Mamos

,

Anna Babińska

,

Agata Bałdys-Waligórska

,

Elżbieta Bandurska-Stankiewicz

,

Krzysztof Błaut

,

Paweł Bolko

,

Wanda Foltyn

,

Danuta Jakubczyk

,

Aleksandra Jawiarczyk-Przybyłowska

,

Roman Junik

,

Olga Juraniec

,

Ewelina Lewkowicz

,

Anna Lewczuk

,

Beata Matyjaszek-Matuszek

,

Krzysztof Michałek

,

Sławomir Mucha

,

Renata Orłowska-Florek

,

Marta Peszel-Barlik

,

Sławomir Pynka

,

Violetta Rosiek

,

Marek Ruchała

,

Joanna Rutkowska

,

Julia Słynko-Krzyzostaniak

,

Agnieszka Stefańska

,

Janusz Strzelczyk

,

Anhelli Syrenicz

,

Małgorzata Trofimiuk-Müldner

,

Joanna Waligórska-Stachura

,

Ryszard Waśko

,

Przemysław Witek

,

Danuta Zalewska-Rydzkowska

,

Piotr Zdunowski

,

Anna Zemczak

Contemp Oncol (Pozn) 2013; 17 (5): 460–465

DOI: https://doi.org/10.5114/wo.2013.38805

Online publish date: 2013/11/14

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Orlewska E, Kos-Kudła B, Sowiński J, et al. Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study. Contemporary Oncology/Współczesna Onkologia. 2013;17(5):460-465. doi:10.5114/wo.2013.38805.

APA

Orlewska, E., Kos-Kudła, B., Sowiński, J., Sworczak, K., Zgliczyński, W.,  & Andrysiak-Mamos, E. et al. (2013). Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study. Contemporary Oncology/Współczesna Onkologia, 17(5), 460-465. https://doi.org/10.5114/wo.2013.38805

Chicago

Orlewska, Ewa, Beata Kos-Kudła, Jerzy Sowiński, Krzysztof Sworczak, Wojciech Zgliczyński, Elżbieta Andrysiak-Mamos,  and Anna Babińska et al. 2013. "Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study". Contemporary Oncology/Współczesna Onkologia 17 (5): 460-465. doi:10.5114/wo.2013.38805.

Harvard

Orlewska, E., Kos-Kudła, B., Sowiński, J., Sworczak, K., Zgliczyński, W., Andrysiak-Mamos, E., Babińska, A., Bałdys-Waligórska, A., Bandurska-Stankiewicz, E., Błaut, K., Bolko, P., Foltyn, W., Jakubczyk, D., Jawiarczyk-Przybyłowska, A., Junik, R., Juraniec, O., Lewkowicz, E., Lewczuk, A., Matyjaszek-Matuszek, B., Michałek, K., Mucha, S., Orłowska-Florek, R., Peszel-Barlik, M., Pynka, S., Rosiek, V., Ruchała, M., Rutkowska, J., Słynko-Krzyzostaniak, J., Stefańska, A., Strzelczyk, J., Syrenicz, A., Trofimiuk-Müldner, M., Waligórska-Stachura, J., Waśko, R., Witek, P., Zalewska-Rydzkowska, D., Zdunowski, P.,  and Zemczak, A. (2013). Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study. Contemporary Oncology/Współczesna Onkologia, 17(5), pp.460-465. https://doi.org/10.5114/wo.2013.38805

MLA

Orlewska, Ewa et al. "Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study." Contemporary Oncology/Współczesna Onkologia, vol. 17, no. 5, 2013, pp. 460-465. doi:10.5114/wo.2013.38805.

Vancouver

Orlewska E, Kos-Kudła B, Sowiński J, Sworczak K, Zgliczyński W, Andrysiak-Mamos E et al. Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study. Contemporary Oncology/Współczesna Onkologia. 2013;17(5):460-465. doi:10.5114/wo.2013.38805.

PlumX metrics:

Aim of the study: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.

Material and methods: A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for  1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013.

Results: 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage – 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/ year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/ patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/patient/ year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/ year). There were 0.43 hospitalizations/patient/year. For direct medical costs estimated at PLN 50 692/patient/ year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care – 49%, hospitalization – 23%, diagnostics/laboratory tests – 28%).

Conclusions: These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden.

keywords:

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study

acromegaly, lanreotide, clinical study, costs of treatment